Literature DB >> 19417222

Apolipoprotein CI is a physiological regulator of cholesteryl ester transfer protein activity in human plasma but not in rabbit plasma.

Jean-Paul Pais de Barros1, Aurélia Boualam, Thomas Gautier, Laure Dumont, Bruno Vergès, David Masson, Laurent Lagrost.   

Abstract

Plasma cholesteryl ester transfer protein (CETP) activity is high in rabbits, intermediate in humans, and nondetectable in rodents. Human apolipoprotein CI (apoCI) was found to be a potent inhibitor of CETP. The aim of this study was to compare the ability of rabbit and human apoCI to modulate the interaction of CETP with HDLs and to evaluate to which extent apoCI contributes to plasma cholesteryl ester transfer rate in normolipidemic humans and rabbits. Rabbit apoCI gene was cloned and sequenced, rabbit and human apoCI were purified to homogeneity, and their ability to modify the surface charge properties and the CETP inhibitory potential of HDL were compared. It is demonstrated that unlike human apoCI, rabbit apoCI does not modulate cholesteryl ester transfer rate in total plasma. Whereas both human and rabbit apoCI readily associate with HDL, only human apoCI was found to modify the electrostatic charge of HDL. In humans, both CETP and apoCI at normal, physiological levels contribute significantly to the plasma cholesteryl ester transfer rate. In contrast, CETP is the sole major determinant of cholesteryl ester transfer in normolipidemic rabbit plasma as a result of the inability of rabbit apoCI to change HDL electronegativity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19417222      PMCID: PMC2724777          DOI: 10.1194/jlr.M800588-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  48 in total

1.  Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.

Authors:  N S Shachter; T Ebara; R Ramakrishnan; G Steiner; J L Breslow; H N Ginsberg; J D Smith
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Influence of the electrostatic charge of lipoprotein particles on the activity of the human plasma phospholipid transfer protein.

Authors:  C Desrumaux; A Athias; D Masson; P Gambert; C Lallemant; L Lagrost
Journal:  J Lipid Res       Date:  1998-01       Impact factor: 5.922

3.  Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphate proteoglycan-bound lipoprotein lipase.

Authors:  F H de Man; F de Beer; A van de Laarse; A H Smelt; J A Leuven; L M Havekes
Journal:  Atherosclerosis       Date:  1998-02       Impact factor: 5.162

4.  Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1.

Authors:  M C Jong; M J Gijbels; V E Dahlmans; P J Gorp; S J Koopman; M Ponec; M H Hofker; L M Havekes
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

5.  In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.

Authors:  M C Jong; V E Dahlmans; P J van Gorp; K W van Dijk; M L Breuer; M H Hofker; L M Havekes
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

6.  Plasma concentration and lipoprotein distribution of ApoC-I is dependent on ApoE genotype rather than the Hpa I ApoC-I promoter polymorphism.

Authors:  Jeffrey S Cohn; Michel Tremblay; Lucie Boulet; Hélène Jacques; Jean Davignon; Madeleine Roy; Lise Bernier
Journal:  Atherosclerosis       Date:  2003-07       Impact factor: 5.162

7.  Evidence for electronegativity of plasma high density lipoprotein-3 as one major determinant of human cholesteryl ester transfer protein activity.

Authors:  D Masson; A Athias; L Lagrost
Journal:  J Lipid Res       Date:  1996-07       Impact factor: 5.922

8.  Cholesterol ester transfer mediated by lipid transfer protein as influenced by changes in the charge characteristics of plasma lipoproteins.

Authors:  H I Nishida; H Arai; T Nishida
Journal:  J Biol Chem       Date:  1993-08-05       Impact factor: 5.157

9.  Comparative study of phospholipid transfer activities mediated by cholesteryl ester transfer protein and phospholipid transfer protein.

Authors:  L Lagrost; A Athias; P Gambert; C Lallemant
Journal:  J Lipid Res       Date:  1994-05       Impact factor: 5.922

10.  Competitive enzyme-linked immunosorbent assay of the human cholesteryl ester transfer protein (CETP).

Authors:  V Guyard-Dangremont; L Lagrost; P Gambert; C Lallemant
Journal:  Clin Chim Acta       Date:  1994-12-16       Impact factor: 3.786

View more
  9 in total

1.  Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease.

Authors:  Xavier Pillois; Thomas Gautier; Benjamin Bouillet; Jean-Paul Pais de Barros; Aline Jeannin; Bruno Vergès; Jacques Bonnet; Laurent Lagrost
Journal:  J Lipid Res       Date:  2012-04-02       Impact factor: 5.922

2.  Protein-Defined Subspecies of HDLs (High-Density Lipoproteins) and Differential Risk of Coronary Heart Disease in 4 Prospective Studies.

Authors:  Frank M Sacks; Liang Liang; Jeremy D Furtado; Tianxi Cai; W Sean Davidson; Zeling He; Robyn L McClelland; Eric B Rimm; Majken K Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-09-10       Impact factor: 8.311

3.  Therapeutic ultrasound: Increased HDL-Cholesterol following infusions of acoustic microspheres and apolipoprotein A-I plasmids.

Authors:  Jason W Castle; Kevin P Kent; Ying Fan; Kirk D Wallace; Cynthia E L Davis; Jeannette C Roberts; Michael E Marino; Kai E Thomenius; Hae W Lim; Eric Coles; Michael H Davidson; Steven B Feinstein; Anthony DeMaria
Journal:  Atherosclerosis       Date:  2015-05-05       Impact factor: 5.162

4.  ApoF knockdown increases cholesteryl ester transfer to LDL and impairs cholesterol clearance in fat-fed hamsters.

Authors:  Richard E Morton; Yan Liu; Lahoucine Izem
Journal:  J Lipid Res       Date:  2019-09-11       Impact factor: 5.922

5.  CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet.

Authors:  Lin Zhu; Thao Luu; Christopher H Emfinger; Bryan A Parks; Jeanne Shi; Elijah Trefts; Fenghua Zeng; Zsuzsanna Kuklenyik; Raymond C Harris; David H Wasserman; Sergio Fazio; John M Stafford
Journal:  Diabetes       Date:  2018-09-13       Impact factor: 9.461

6.  The structure of human apolipoprotein C-1 in four different crystal forms.

Authors:  Alexander McPherson; Steven B Larson
Journal:  J Lipid Res       Date:  2018-12-17       Impact factor: 5.922

Review 7.  Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond.

Authors:  Elena V Fuior; Anca V Gafencu
Journal:  Int J Mol Sci       Date:  2019-11-26       Impact factor: 5.923

8.  Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.

Authors:  Jeremy D Furtado; Giacomo Ruotolo; Stephen J Nicholls; Robert Dullea; Santos Carvajal-Gonzalez; Frank M Sacks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-12-23       Impact factor: 8.311

9.  Plasma proteoforms of apolipoproteins C-I and C-II are associated with plasma lipids in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Juraj Koska; Jeremy Furtado; Yueming Hu; Shripad Sinari; Matthew J Budoff; Dean Billheimer; Dobrin Nedelkov; Robyn L McClelland; Peter D Reaven
Journal:  J Lipid Res       Date:  2022-08-09       Impact factor: 6.676

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.